Urology Associates of Sacramento - RAS
916-454-6600
 

Concurrent chemo and radiation therapy improves long-term survival for inoperable stage III lung cancer

Sep 8, 2011
The study conducted by the Radiation Therapy Oncology Group (RTOG 9410) is the largest randomized trial to confirm the importance of administering chemotherapy and radiotherapy concurrently rather than sequentially for patients with locally-advanced non-small cell lung cancer (NSCLC).

Sacramento Area Physician is Principal Investigator and Lead Author on New Prostate Cancer Research

Jul 14, 2011
Radiological Associates of Sacramento (RAS) announced today that Christopher Jones, M.D., Radiation Oncologist, was principal investigator and lead author on significant prostate cancer research published today in the New England Journal of Medicine.

RAS One of Five Centers Nationwide to Test SBRT For Prostate Cancer

Jul 13, 2011
A new treatment approach that could shorten the course of radiation treatment for prostate cancer will be tested at the Radiation Oncology Division of Radiological Associates of Sacramento Medical Group, Inc. (RAS).

Large randomized phase III clinical trial shows short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer

Jul 13, 2011
Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in today’s New England Journal of Medicine.

RAS Among First in the Nation to Treat Advanced Prostate Cancer Patients with PROVENGE®

Jul 7, 2011
RAS’ Clinic for Hematology and Medical Oncology, commonly referred to as SCHMO, is the first provider in Northern California, and among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. PROVENGE® was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.

CT screening reduces lung-cancer deaths in heavy smokers

Feb 4, 2011
Studying heavy smokers, the National Cancer Institute’s 33-center National Lung Screening Trial found that significantly fewer who were screened with low-dose CT scans died from lung cancer than heavy smokers screened with standard chest X-rays.

Roseville Radiation Oncology Center (ROC) Redefines Efficiency With ELEKTA VMAT Radiotherapy Treatments

Feb 18, 2010
The first treatments with Elekta Volumetric Modulated Arc Therapy (VMAT) begins at Radiological Associates of Sacramento (RAS). With Elekta VMAT, single or multiple radiation beams sweep in uninterrupted arc(s) around the patient, reducing treatment times.

Stereotactic Body Radiation Therapy (SBRT) offers an advanced alternative to surgery for stage 1 lung cancer

Nov 1, 2009
New treatment method available through RAS’ Radiation Oncology Centers